ArticleSisli Etfal Hastanesi tip bulteni2024
Endovascular Treatment in Symptomatic Intracranial Artery Stenosis: Experience from Two Centers.
Article in Sisli Etfal Hastanesi tip bulteni, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the efficacy of endovascular treatment and clinical outcomes in individuals with symptomatic intracranial stenosis who had not responded adequately to medical intervention. Methods: The study included 32 patients who received endovascular treatment due to high-grade (70%-99% severity) intracranial atherosclerotic stenosis from December 2021 to December 2023. The patients had not experienced any acute ischemic or hemorrhagic infarction within the last three weeks, had a Modified Rankin Scale score of ≤3 at baseline, and developed a transient ischemic attack or non-disabling stroke despite having received the best medical treatment. Technical and clinical success, mortality, and complication rates were recorded. Results: Of the 32 patients included in the study, 62.5% (n=20) were male, and the mean age was 66.4±10.09 years. Stenting was performed on the intracranial internal carotid artery in 43.8% (n=14) of the patients, the intradural vertebral artery in 37.5% (n=12), the middle cerebral artery in 12.5% (n=4), and the basilar artery in 6.3% (n=2). The technical success rate was 100%, and the clinical success rate was 87.5%. The mean degree of stenosis before the procedure was 91.7±6.3%, and the degree of residual stenosis after the procedure was 22.1±4.7%. The Neuroform Atlas® stent system was used in 18 cases (56.3%), Credo® stents in eight (25%), coronary balloon-expandable stents in four (12.5%), and the LVIS® stent system in two (6.3%). Twenty-eight (87.5%) patients did not have any symptoms in the first 30 days, while two (6.2%) patients had an ischemic stroke, one (3.1%) patient had a hemorrhagic stroke, and one (3.1%) died. Conclusion: Endovascular treatment in carefully selected patients, a tailored selection of treatment subtypes, and an experienced multidisciplinary team overseeing the patient before, during, and after the procedure have the potential to provide safe and effective treatment for patients with symptomatic intracranial atherosclerotic stenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.